TY - JOUR
T1 - Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders
AU - Dölle, Anja
AU - Adhikari, Bikash
AU - Krämer, Andreas
AU - Weckesser, Janik
AU - Berner, Nicola
AU - Berger, Lena Marie
AU - Diebold, Mathias
AU - Szewczyk, Magdalena M.
AU - Barsyte-Lovejoy, Dalia
AU - Arrowsmith, Cheryl H.
AU - Gebel, Jakob
AU - Löhr, Frank
AU - Dötsch, Volker
AU - Eilers, Martin
AU - Heinzlmeir, Stephanie
AU - Kuster, Bernhard
AU - Sotriffer, Christoph
AU - Wolf, Elmar
AU - Knapp, Stefan
N1 - Publisher Copyright:
© 2021 American Chemical Society.
PY - 2021/8/12
Y1 - 2021/8/12
N2 - Histone H3K4 methylation serves as a post-translational hallmark of actively transcribed genes and is introduced by histone methyltransferase (HMT) and its regulatory scaffolding proteins. One of these is the WD-repeat-containing protein 5 (WDR5) that has also been associated with controlling long noncoding RNAs and transcription factors including MYC. The wide influence of dysfunctional HMT complexes and the typically upregulated MYC levels in diverse tumor types suggested WDR5 as an attractive drug target. Indeed, protein-protein interface inhibitors for two protein interaction interfaces on WDR5 have been developed. While such compounds only inhibit a subset of WDR5 interactions, chemically induced proteasomal degradation of WDR5 might represent an elegant way to target all oncogenic functions. This study presents the design, synthesis, and evaluation of two diverse WDR5 degrader series based on two WIN site binding scaffolds and shows that linker nature and length strongly influence degradation efficacy.
AB - Histone H3K4 methylation serves as a post-translational hallmark of actively transcribed genes and is introduced by histone methyltransferase (HMT) and its regulatory scaffolding proteins. One of these is the WD-repeat-containing protein 5 (WDR5) that has also been associated with controlling long noncoding RNAs and transcription factors including MYC. The wide influence of dysfunctional HMT complexes and the typically upregulated MYC levels in diverse tumor types suggested WDR5 as an attractive drug target. Indeed, protein-protein interface inhibitors for two protein interaction interfaces on WDR5 have been developed. While such compounds only inhibit a subset of WDR5 interactions, chemically induced proteasomal degradation of WDR5 might represent an elegant way to target all oncogenic functions. This study presents the design, synthesis, and evaluation of two diverse WDR5 degrader series based on two WIN site binding scaffolds and shows that linker nature and length strongly influence degradation efficacy.
UR - http://www.scopus.com/inward/record.url?scp=85106535073&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.1c00146
DO - 10.1021/acs.jmedchem.1c00146
M3 - Article
C2 - 33980013
AN - SCOPUS:85106535073
SN - 0022-2623
VL - 64
SP - 10682
EP - 10710
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 15
ER -